<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cannabinoid Research References</title>
    <style>
        /* ... (keep the same CSS styles as before) ... */
    </style>
</head>
<body>
    <div class="container">
        <h1>Cannabinoid Research References</h1>
        
        <div class="qr-container">
            <input type="text" id="website-url" 
                   placeholder="Enter website URL" 
                   value="https://chronoxzx.github.io/cannabinoid-references/">
            <div id="qrcode"></div>
        </div>

        <div class="references">
            <!-- Reference 1 -->
            <div class="reference" id="ref1">
                <h3>[1] García C, et al. (2016)</h3>
                <p><em>Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia</em></p>
                <p>British Journal of Pharmacology 173(13):2069-2079</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1111/bph.13270" target="_blank">10.1111/bph.13270</a></p>
            </div>

            <!-- Reference 2 -->
            <div class="reference" id="ref2">
                <h3>[2] Patricio F, et al. (2020)</h3>
                <p><em>Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease</em></p>
                <p>Frontiers in Pharmacology 11</p>
                <p class="doi">DOI: <a href="https://doi.org/10.3389/fphar.2020.595635" target="_blank">10.3389/fphar.2020.595635</a></p>
            </div>

            <!-- Reference 3 -->
            <div class="reference" id="ref3">
                <h3>[3] Cooray R, et al. (2020)</h3>
                <p><em>Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: a review</em></p>
                <p>Molecular Neurobiology 57(8):4878-4890</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1007/s12035-020-02054-6" target="_blank">10.1007/s12035-020-02054-6</a></p>
            </div>

            <!-- Reference 4 -->
            <div class="reference" id="ref4">
                <h3>[4] Stampanoni Bassi M, et al. (2017)</h3>
                <p><em>Cannabinoids in Parkinson’s disease</em></p>
                <p>Cannabis and Cannabinoid Research 2(1):21-29</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1089/can.2017.0002" target="_blank">10.1089/can.2017.0002</a></p>
            </div>

            <!-- Reference 5 -->
            <div class="reference" id="ref5">
                <h3>[5] Ye L, et al. (2019)</h3>
                <p><em>New Insights in Cannabinoid Receptor Structure and Signaling</em></p>
                <p>Current Molecular Pharmacology 12(3):239-248</p>
                <p class="doi">DOI: <a href="https://doi.org/10.21741/1874467212666190215112036" target="_blank">10.21741/1874467212666190215112036</a></p>
            </div>

            <!-- Reference 6 -->
            <div class="reference" id="ref6">
                <h3>[6] de Almeida DL, Devi LA. (2020)</h3>
                <p><em>Diversity of molecular targets and signaling pathways for CBD</em></p>
                <p>Pharmacology Research & Perspectives 8(6):e00682</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1002/prp2.682" target="_blank">10.1002/prp2.682</a></p>
            </div>

            <!-- Reference 7 -->
            <div class="reference" id="ref7">
                <h3>[7] Wi R, et al. (2020)</h3>
                <p><em>Functional crosstalk between CB and TRPV1 receptors protects nigrostriatal dopaminergic neurons in the MPTP model of Parkinson’s disease</em></p>
                <p>Journal of Immunology Research 2020:5093493</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1155/2020/5093493" target="_blank">10.1155/2020/5093493</a></p>
            </div>

            <!-- Reference 8 -->
            <div class="reference" id="ref8">
                <h3>[8] Giuliano C, et al. (2021)</h3>
                <p><em>Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease</em></p>
                <p>International Journal of Molecular Sciences 22(16):8920</p>
                <p class="doi">DOI: <a href="https://doi.org/10.3390/ijms22168920" target="_blank">10.3390/ijms22168920</a></p>
            </div>

            <!-- Reference 9 -->
            <div class="reference" id="ref9">
                <h3>[9] García C, et al. (2011)</h3>
                <p><em>Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease</em></p>
                <p>British Journal of Pharmacology 163(7):1495–1506</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1111/j.1476-5381.2011.01278.x" target="_blank">10.1111/j.1476-5381.2011.01278.x</a></p>
            </div>

            <!-- Reference 10 -->
            <div class="reference" id="ref10">
                <h3>[10] Peball M, et al. (2020)</h3>
                <p><em>Non-motor symptoms in Parkinson’s disease are reduced by nabilone</em></p>
                <p>Annals of Neurology 88(4):712-722</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1002/ana.25864" target="_blank">10.1002/ana.25864</a></p>
            </div>

            <!-- Reference 11 -->
            <div class="reference" id="ref11">
                <h3>[11] Viveros-Paredes JM, et al. (2019)</h3>
                <p><em>Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage</em></p>
                <p>Neurología 34(3):143-152</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1016/j.nrl.2016.11.003" target="_blank">10.1016/j.nrl.2016.11.003</a></p>
            </div>

            <!-- Reference 12 -->
            <div class="reference" id="ref12">
                <h3>[12] Ren S, et al. (2020)</h3>
                <p><em>Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors</em></p>
                <p>Acta Pharmacologica Sinica 41(10):1263-1271</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1038/s41401-020-0385-7" target="_blank">10.1038/s41401-020-0385-7</a></p>
            </div>
        </div>
    </div>

    <script src="https://cdn.rawgit.com/davidshimjs/qrcodejs/gh-pages/qrcode.min.js"></script>
    <script>
        // ... (keep the same JavaScript code as before) ...
    </script>
</body>
</html>
